protein tyrosine phosphatase non-receptor type 13Genealiases: FAP-1 · PNP1 · PTP-BAS · PTP-BL · PTP1E · PTPL1
Q-omics provides the consensus-scored PTPN13 profile across patient tissues and cancer cell-line models. PTPN13 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PTPN13 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, PTPN13 RNA expression shows 20,314 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, KIRC, and KIRP as cancer lineages where PTPN13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPN13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPN13 survival associations across molecular data types. PTPN13 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPN13 RNA expression–survival associations across cancer types. High PTPN13 expression shows unfavorable associations in UVM, UCEC, LGG and MESO, but favorable associations in HNSC and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PTPN13 RNA expression.
This table summarizes PTPN13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PTPN13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPN13 shows lower tumor expression in KIRC, LUAD, KICH, THCA and KIRP and higher tumor expression in COAD. The KIRC box plot shows higher PTPN13 RNA expression in normal versus tumor tissue (log2 FC = −1.473, t-test p < 0.001).
This table shows molecular features associated with PTPN13 in patient tissues and cancer cell lines. In patient samples, PTPN13 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPN13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
